Notre groupe organise plus de 3 000 séries de conférences Événements chaque année aux États-Unis, en Europe et en Europe. Asie avec le soutien de 1 000 autres Sociétés scientifiques et publie plus de 700 Open Access Revues qui contiennent plus de 50 000 personnalités éminentes, des scientifiques réputés en tant que membres du comité de rédaction.
Les revues en libre accès gagnent plus de lecteurs et de citations
700 revues et 15 000 000 de lecteurs Chaque revue attire plus de 25 000 lecteurs
Ulrich Kutschera
It is a chronic childhood disorder with numerous possible causes. Injury to the developing brain during pregnancy or shortly after birth can cause the motor, sensory, and cognitive deficits associated with cerebral palsy. Even though the causes of cerebral palsy vary, neuroinflammation plays a critical role in the pathophysiology of brain injury. Cerebral palsy currently has no effective treatment. Nanomedicine provides a new avenue for research and development of treatments for brain injury that causes cerebral palsy. Dendrimers and other nanomaterials allow multiple drugs to be delivered precisely to the cells responsible for neuroinflammation and injury, reducing the number of injury-related pathways. Furthermore, these materials allow for the delivery of agents that promote brain repair and regeneration, reducing injury and facilitating normal growth. The most recent advances in nanotechnology for the treatment of brain injuries, with a focus on cerebral palsy, are discussed. Possible future directions for making clinical translation easier for children and newborns are also discussed.